相关实验视频
Updated: Sep 13, 2025

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
350
基于三重激进主义的肥胖治疗方法
Jonathan Goldney1,2, Malak Hamza1,2, Farhaana Surti1,2
1Diabetes Research Centre, College of Life Sciences, University of Leicester, Leicester General Hospital, Leicester, LE5 4PW UK.
Current cardiovascular risk reports
|July 31, 2025
概括
雷塔鲁提德是一种三重因克列激动剂,在肥胖和2型糖尿病中显示出显著的体重减轻和改善血糖控制. 这种新疗法也有利于心脏代谢标志物,目前正在进行的第三阶段试验评估长期结果.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
背景情况:
- 葡萄糖类1 (GLP-1) 受体激动剂 (RA) 已经彻底改变了肥胖和2型糖尿病 (T2D) 管理.
- 蒂尔泽帕提德是一种双GLP-1/依赖葡萄糖的胰岛素型多 (GIP) RA,它代表了基于英克雷丁的疗法的重大进步.
- 针对GLP-1,GIP和葡萄糖素受体的三重激动剂正在成为有希望的下一代治疗方法.
研究的目的:
- 审查三重增蛋白激动剂开发背后的逻辑.
- 为了总结临床试验数据的retatrutide,一个领先的三重激动剂候选人.
- 突出雷达在控制肥胖,T2D和相关心脏代谢风险因素方面的潜力.
主要方法:
- 对已公布的临床试验数据的审查,重点关注复原二期研究.
- 在减肥,血糖控制 (HbA1c) 和心脏代谢参数方面分析雷达的疗效.
- 评估雷达的安全性概况和常见不良事件.
主要成果:
- 雷塔鲁提德证明了实质性的平均体重减轻:高达24.2%的肥胖和16.9%的T2D.
- 在T2D中显著改善HbA1c (2.2%),其中82%的人达到HbA1c ≤6.5%.
- 血压,脂质,腰围和肝硬化 (82%的减少) 显著改善.
结论:
- 雷塔特鲁提德是第一个有发布的二期数据的三重激动剂,它对体重和代谢健康产生强有力的影响.
- 胃肠道症状是最常见的副作用;没有发现重大安全问题.
- 目前正在进行第三阶段试验,以确认疗效,安全性和心血管/结局,将复原定位为肥胖和T2D的潜在主要治疗方法.
相关概念视频
Drug-Receptor Interaction: Agonist
2.8K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.8K
Glucagon-like Receptor Agonists
420
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
420
Obesity
620
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
620
Antidepressant Drugs: MAOIs and Other Agents
358
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
358
Adrenergic Agonists: Therapeutic Uses
967
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
967
Agonism and Antagonism: Quantification
572
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
572

